SARS Cov2 Infection and Preeclampsia. How an Infection Can Help Us To Know More About an Obstetric Condition
Preprint
- 2 May 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
In this review, we aimed to understand the relationship between SARS-CoV-2 infection and preeclampsia severity in infected pregnant women. Pregnant women with SARS- CoV-2 infection have been shown to have a significantly increased risk of maternal death, ICU admission, preterm delivery, and stillbirth compared with those without infection. The risk of preeclampsia also increases in pregnant women infected with SARS-CoV-2, particularly in those with severe symptoms. We emphasize the im-portance of specialized clinical management to prevent poor pregnancy outcomes in this situation. The association between COVID-19 and preeclampsia (PE) is likely due to multiple mechanisms, including the direct effects of the virus on trophoblast function and the arterial wall, acute atherosis, local inflammation leading to pla-cental ischemia, exaggerated inflammatory responses in pregnant women, SARS-CoV-2-related myocardial injury, cytokine storm, and thrombotic microan-giopathy. Emphasis has been placed on the potential impact of COVID-19 on pregnant women, specifically in relation to thrombotic complications, placental dysfunction, and cardiovascular dysfunction. Undoubtedly, one of the diagnostic tools to differentiate between COVID-19-induced preeclampsia-like syndrome and true preeclampsia is the use of biomarkers, such as the sFlt-1/PlGF ratio. We wish to highlight the potential for COVID-19-induced myocardial injury in pregnant women and the associated in-crease in maternal mortality rate. Vaccination against COVID-19 in the general population and in pregnant women in particular, drastically reduced the severity of the disease. There is an urgent need to continue the follow-up of these women and their children to detect the appearance of sequelae of the disease or peristent COVID 19Keywords
All Related Versions
- Version 1, 2023-05-02, Preprints
- Published version: Viruses, 15 (7), 1564.
This publication has 43 references indexed in Scilit:
- Cardiovascular determinants of impaired placental function in women with cardiac dysfunctionAmerican Heart Journal, 2022
- COVID‐19: A new risk factor or just a new imitator of preeclampsia? NLRP3 activation: A possible common mechanismJournal of Medical Virology, 2022
- The placenta and preeclampsia: villain or victim?American Journal of Obstetrics and Gynecology, 2022
- Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 InfectionJAMA Pediatrics, 2021
- New-onset myocardial injury in pregnant patients with coronavirus disease 2019: a case series of 15 patientsAmerican Journal of Obstetrics and Gynecology, 2021
- Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsiaAmerican Journal of Obstetrics and Gynecology, 2021
- SFLT‐1 levels in COVID‐19 patients: Association with outcome and thrombosisAmerican Journal of Hematology, 2020
- COVID‐19 and the heart: An update for cliniciansClinical Cardiology, 2020
- Maternal left ventricular hypertrophy and diastolic dysfunction and brain natriuretic peptide concentration in early‐ and late‐onset pre‐eclampsiaUltrasound in Obstetrics & Gynecology, 2018
- Maternal and Fetal Outcomes of Admission for Delivery in Women With Congenital Heart DiseaseJAMA Cardiology, 2017